Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD8701 |
Synonyms | |
Therapy Description |
AZD8701 is an antisense oligonucleotide that targets FOXP3 and modulates expression of its target genes, which potentially results in reduced immunosuppession (Cancer Res 2019;79(13 Suppl):Abstract nr 2713). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD8701 | AZD-8701|AZD 8701 | Antisense Therapy 14 | AZD8701 is an antisense oligonucleotide that targets FOXP3 and modulates expression of its target genes, which potentially results in reduced immunosuppession (Cancer Res 2019;79(13 Suppl):Abstract nr 2713). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04504669 | Phase I | AZD8701 + Durvalumab AZD8701 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | Completed | USA | FRA | ESP | CAN | 0 |